$69 non-ATF Mobile


  • Digital healthcare service provider ResApp Health Limited announced the signing of a non-exclusive marketing agreement with Australia’s largest consumer healthcare network, HealthEngine.
  • As part of the agreement, HealthEngine’s booking engine will be integrated with ResApp’s SleepCheck, a mobile medical application.
  • ResApp will retain the revenue derived from the download of SleepCheck. Also, it will get a share of the revenue from HealthEngine for each new patient referred.
Gold MTF non-AMP

The share price of small-cap healthcare ResApp Health Limited (ASX:RAP) moved north following the Company’s announcement that it had signed a non-exclusive marketing agreement with HealthEngine. HealthEngine is the largest consumer healthcare network across Australia.

On 21 October 2020, the share price of RAP was noted at A$0.105 up by ~5%, with a market capitalisation of A$75.81 million.

Let us dive deep and discuss ResApp’s agreement in detail-

About ResApp Health

ASX-listed digital health player ResApp Health Limited is engaged in developing smartphone-based applications to diagnose as well as manage the respiratory indications. The machine learning algorithms of ResApp diagnose and measure the severity of respiratory conditions by using sound, requiring no additional accessories or hardware.

ResApp’s clinically validated products include ResAppDx-EU and SleepCheck. These are TGA (Therapeutic Good Administration) approved in Australia and CE Marked in Europe.

ResApp’s marketing agreement with HealthEngine

On 21 October 2020, ResApp Health Limited disclosed that it had signed a non-exclusive marketing agreement with Australia’s patient network, HealthEngine. The agreement has been signed for 12 months.

The Company revealed that the agreement with HealthEngine aims to integrate its booking engine into SleepCheck, the mobile medical application of ResApp. In return, HealthEngine will also encourage the use of ResApp’s SleepCheck.

SleepCheck is an easy-to-use, direct-to-consumer mobile application that utilises accurate algorithms for assessing the risk of OSA (obstructive sleep apnoea) in a person by analysing breathing and snoring sounds during sleep. Besides, it does not require any accessories or hardware for the assessment, other than the user’s smartphone.

The new revenue stream for ResApp Health

The revenue-sharing model generates a new revenue stream for ResApp Health and offers the Company with another partnership agreement to strengthen the scale-up of the SleepCheck application.

The agreement also validates the Company’s offering from a top tier Australian digital healthcare player. This agreement can be extended by both companies.

The revenue from the agreement cannot be estimated at this early stage and is dependent on new patients referred to HealthEngine via SleepCheck. However, ResApp is confident of substantial consumer uptake.

ResApp’s CEO and Managing Director Dr Tony Keating stated-

ResApp’s partnership with Australia’s largest consumer healthcare network is a tremendous achievement for the Company, and it also highlights a huge potential for SleepCheck across the Australian market. Further, the agreement also provides great validation of ResApp’s services from another industry-leading partner.


With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.



The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK